Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Pharmacology|May 15, 1999
Use of diffusion-weighted MRI and neurological deficit scores to demonstrate beneficial effects of isradipine in a rat model of focal ischemiaS Chandra, R F White, D Everding, et al.Osteoarthritis and Cartilage|September 1, 2000
Meniscal ossification in spontaneous osteoarthritis in the guinea-pigR D Kapadia, A M Badger, J M Levin, et al.Circulation|September 12, 2000
Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failureT M Behr, X Wang, N Aiyar, et al.Journal of Cardiovascular Pharmacology|October 6, 2001
Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunctionR N Willette, K M Anderson, A H Nelson, et al.Journal of Cardiovascular Pharmacology|November 15, 2000
Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primateS A Douglas, D J Ashton, C F Sauermelch, et al.Technology and Health Care : Official Journal of the European Society for Engineering and Medicine|April 1, 1999
Applications of micro-CT and MR microscopy to study pre-clinical models of osteoporosis and osteoarthritisR D Kapadia, G B Stroup, A M Badger, et al.Cardiovascular Research|May 30, 2001
Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone ratsF C Barone, R W Coatney, S Chandra, et al.Circulation|September 12, 2001
Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunctionT M Behr, S S Nerurkar, A H Nelson, et al.Nature|September 28, 1999
Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14R S Ames, H M Sarau, J K Chambers, et al.Pageof 2